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A role for the extended amygdala in the fear-enhancing
effects of acute selective serotonin reuptake inhibitor
treatment
S Ravinder1,4, NS Burghardt2,4, R Brodsky3, EP Bauer3 and S Chattarji1
Selective serotonin reuptake inhibitors (SSRIs) are reported to exacerbate symptoms of anxiety when treatment is initiated.
These clinical findings have been extended to animal models wherein SSRIs also potentiate anxiety and fear learning, which
depend on the amygdala. Yet, little is known about the role of specific amygdalar circuits in these acute effects of SSRIs. Here, we
first confirmed that a single injection of fluoxetine 1 h before auditory fear conditioning potentiated fear memory in rats. To probe
the neural substrates underlying this enhancement, we analyzed the expression patterns of the immediate early gene, Arc
(activity-regulated cytoskeleton-associated protein). Consistent with previous reports, fear conditioning induced Arc protein
expression in the lateral and basal amygdala. However, this was not enhanced further by pre-treatment with fluoxetine. Instead,
fluoxetine significantly enhanced expression of Arc in the central amygdala (CeA) and the bed nucleus of the stria terminalis
(BNST). Next, we tested whether direct targeted infusions of fluoxetine into the CeA, or BNST, leads to the same fear-potentiating
effect. Strikingly, direct infusion of fluoxetine into the BNST, but not the CeA, was sufficient to enhance fear memory. Moreover,
this behavioral effect was also accompanied by robust Arc expression in the CeA, similar to the systemic injection. Our results
identify a novel role for the BNST in the acute fear-enhancing effects of SSRIs. These findings highlight the need to look beyond
the traditional focus on input nuclei of the amygdala and add to accumulating evidence implicating these microcircuits in gating
fear and anxiety.
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Introduction
Antidepressant drugs, such as selective serotonin reuptake
inhibitors (SSRIs), are commonly administered for treating a
range of anxiety disorders.1–4 Although long-term treatment
with SSRIs yields therapeutic benefits, they exacerbate
symptoms of anxiety when treatment is initiated, potentially
leading to an increased risk of suicidal ideation.5–10 Although
the acute anxiogenic effects of SSRIs have been demon-
strated in numerous rodent models of anxiety-like beha-
vior,11–15 the cellular substrates of these acute effects are
largely unknown.
Acute SSRI treatment, before auditory fear conditioning,
leads to stronger fear memory,16 which is consistent with its
known anxiogenic effects. Auditory fear conditioning offers a
significant advantage as a robust model of associative
emotional learning, as the neural circuitry and molecular
mechanisms have been elucidated in detail in the amyg-
dala.17–20 The lateral nucleus of the amygdala (LA) serves as
the major input interface receiving sensory information from
the thalamus and cortex.21,22 Information processed within
the LA and basal nucleus of the amygdala (BA) is then relayed
to output structures. The central nucleus of the amygdala
(CeA) and the bed nucleus of the stria terminalis (BNST),
which together comprise the extended amygdala, serve as the
principal output structures of the amygdaloid complex that
project to the brainstem and hypothalamus and mediate the
expression of fear responses.23,24 While the CeA mediates
expression of conditioned fear responses to brief stimuli, the
BNST mediates generalized and sustained fear responses to
more diffuse stimulus contingencies.25,26
Current understanding of the cellular and circuit
mechanisms of fear conditioning gives rise to several
predictions about how acute treatment with SSRIs may
enhance fear memory. Plasticity in the LA is crucial for the
formation of conditioned fear memory.20 Activity-regulated
cytoskeleton-associated protein (Arc), a plasticity-related
immediate early gene (IEG), is induced by auditory fear
conditioning, in the LA and BA, and is essential for fear
memory expression.27 Thus, SSRIs may potentiate fear
memory by enhancing Arc expression in the LA or BA.
Alternatively, SSRIs may affect the output nuclei, which have
also been implicated in fear memory formation.19,28,29 In this
study, we explore these possibilities by combining auditory
fear conditioning, systemic treatment and targeted infusions
of the SSRI fluoxetine into the amygdala and analysis
of Arc expression patterns to identify components of the
amygdalar fear circuitry that may underlie the acute beha-
vioral effects of SSRIs.
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Materials and methods
Subjects. Male Sprague–Dawley rats (250–300 g) were
housed in groups of two or three with ad libitum access to
food and water. All animal experiments were conducted at
the National Centre for Biological Sciences (NCBS) with the
exception of experiments involving local drug infusions,
which were carried out at the animal facility at Barnard
College. Animals were maintained in a temperature-con-
trolled room, with a 14/10-h day/night cycle at NCBS and 12/
12-h day/night cycle at the Barnard College animal facility. All
procedures were approved by the Institutional Animal Ethics
Committee for NCBS or Columbia University’s Animal Care
and Use Committee.
Drug administration. Fluoxetine hydrochloride was
obtained from Hikal Ltd (Bangalore, India) and Sigma-Aldrich
(St Louis, MO, USA).
Systemic injections. For systemic drug administration, fluox-
etine was dissolved in 0.9% sterile saline and injected
intraperitoneally (i.p.) at a dose of 10 mg kg 1.28–30
Local drug infusions. Cannulae were surgically implanted to
locally infuse fluoxetine or saline into the CeA or BNST. Rats
were anesthetized and maintained in deep anesthesia with a
mixture of isoflurane and oxygen and placed in a stereotaxic
apparatus. Body temperature was maintained with a heated
gel pad. Betadine was applied to the scalp and a local
anesthetic (bupivicaine, subcutaneous) was injected under
the scalp. The skull was exposed, and small holes
were drilled. Stainless steel guide cannulae (22 gauge;
Plastics One, Roanoke, VA, USA) fitted with infusion
cannulae (28 gauge) that extended (2 mm) beyond the base
of the guide were positioned bilaterally above the CeA
( 2.5 mm anteroposterior (AP), þ / 4.3 mm mediolateral
(ML),  8.0 mm dorsoventral (DV)) or BNST ( 0.6 mm AP,
þ / 1.5 ML,  6.5 mm DV).31 The guide cannulae were
secured to the skull using surgical screws and acrylic dental
cement. Infusion cannulae were replaced with dummy
cannulae that did not extend beyond the guide cannulae to
prevent clogging. After surgery, rats received an analgesic
(carprofen, 5 mg kg 1, i.p.) and 5 ml of lactated ringer
(subcutaneous) and recovered for 1 week before drug
infusion and behavioral testing.
Fluoxetine was infused into the CeA or BNST at a dose of 6
or 9 mg per side (in 0.5ml saline). This choice of dose was
based on the behavioral effects reported by earlier studies
that have infused fluoxetine directly into the brain at these
doses.32,33 The drug solution was infused at a rate of
2ml min 1 through infusion cannulae attached to a 1-ml
Hamilton syringe via polyethylene tubing. The cannulae were
left in place for an additional 2 min after the infusion to allow for
diffusion of the solution away from the cannula tip, after which
the dummy cannulae were replaced and the rat was returned
to its home cage.
To verify the placement of the injection cannula tips
after behavioral testing, rats were anesthetized with Euthasol
(containing pentobarbital; 100 mg kg 1, i.p.) and transcar-
dially perfused with 0.9% saline followed by ice-cold
4% paraformaldehyde in phosphate-buffered saline (PBS).
Brains were removed and stored in 4% paraformaldehyde for
24 h and then cryoprotected in 20% followed by 30% sucrose
(in 0.1 M phosphate buffer, pH 7.4). Subsequently, brains were
blocked and cut in 60 mm sections through the CeA or BNST
using a cryostat. After standard histological Nissl or hematox-
ylin staining, sections were examined on a light microscope to
localize the cannula tip.
Behavioral procedures
Apparatus and stimuli. Rats were fear conditioned in
chambers made of aluminium and Plexiglass walls with
stainless steel rod flooring attached to a shock generator
(Coulbourn Instruments, Allentown, PA, USA). The chamber
was illuminated by an overhead yellow light, all of which was
located within a sound attenuating box (Coulbourn Instru-
ments). The testing context was made distinct by changing
the walls, floors, lighting and introducing a peppermint
odor to the chamber. A video camera was used to record
behavioral conditioning and testing sessions for subsequent
offline analysis. Stimulus presentation was controlled by a
computer with Graphic State 2 software (Coulbourn Instru-
ments). The conditioning and testing chambers were
thoroughly cleaned with alcohol between sessions.
Fear conditioning. For experiments involving systemic drug
administration, auditory fear conditioning consisted of a 3-
day procedure. On day 1, all rats were first habituated to the
conditioning chamber followed by the testing chamber for
10 min. On day 2, rats were injected with fluoxetine or saline,
and 60 min later they were fear conditioned in the condition-
ing chamber. Fear conditioning involved five pairings of a
conditioned stimulus (CS; 5 kHz tone, 75 db, 20 s) that co-
terminated with an unconditioned stimulus (0.5 mA foot-
shock, 0.5 s). The inter-trial interval varied randomly between
60 and 120 s. On day 3, rats were placed in the testing
chamber where they received three CS presentations with an
inter-trial interval that varied randomly between 60 and 120 s.
Behavior during the conditioning and testing sessions was
videotaped for subsequent manual off-line analysis of
freezing behavior. Freezing, defined as cessation of all
movement except for respiration, was used as a measure of
conditioned fear. Freezing is reported as a percentage of
total tone presentation time.
For the local drug infusion experiments, rats were allowed
to recover for 1 week after the surgery. On day 1, rats were
habituated to the conditioning chamber for 20 min. On day 2,
rats were infused with fluoxetine or saline 15 min before they
were fear conditioned with two pairings of the CS (5 kHz tone,
75 db, 30 s) and unconditioned stimulus (0.5 mA footshock,
0.5 s). On day 3, they were tested in the testing chamber with
10 CS presentations.
Immunohistochemistry. Two hours after the conditioning
session, rats were killed and their brains were analyzed for
behaviorally induced Arc protein expression. The 2-h time
point after fear conditioning was chosen to examine Arc
expression based on an earlier study that reported an
induction of Arc protein expression in the LA and BA 2 h
after fear conditioning.27 Rats were deeply anesthetized with
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halothane followed by ketamine (0.05 ml per 100 g, i.p.) and
xylazine (0.2 ml per 100 g, i.p.) and transcardially perfused
with 0.1 M PBS, followed by ice-cold 4% paraformaldehyde–
PBS. Brains were removed and postfixed in 4%
paraformaldehyde–PBS for 24 h and then cryoprotected in
20% followed by 30% sucrose (in 0.1 M phosphate buffer, pH
7.4). A cryostat was used to cut 40-mm thick coronal brain
sections containing the amygdala. Every sixth section was
then processed for Arc immunoreactivity. After blocking in
PBS containing 1% bovine serum albumin (BSA Fraction V,
Sigma-Aldrich)-0.1% Triton X-100, slices were incubated
overnight at room temperature in anti-Arc primary antibody
(mouse monoclonal, 1:1000 dilution; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) in PBS-1% BSA-0.1% Triton
X-100. Sections were then incubated with a biotinylated
secondary antibody (anti-mouse IgG, 1:200 dilution, Vectas-
tain Elite ABC kit, Vector Laboratories, Burlingame, CA,
USA) for 1 h at room temperature. Arc-expressing cells were
then visualized using VectaStain Elite ABC kit (Vector
Laboratories) followed by DAB staining (DAB peroxidase
substrate, Vector Laboratories). Sections were then mounted
onto Fisherbrand electrostatic slides. Sections from compar-
able anterior–posterior levels were selected for scoring
( 2.04 to  2.92 mm posterior to Bregma for the CeA,
0.36 to  0.96 mm posterior to Bregma for the BNST and
 2.92 and  3.96 mm posterior to Bregma for the dentate
gyrus (DG)). Cell counts were taken from at least three
sections (six hemispheres) per rat. Cells were counted
manually using the NeuroLucida image analysis system
(MicroBrightField, Wiliston, VT, USA) attached to an Olym-
pus BX61 microscope (Olympus, Tokyo, Japan;  40, 0.75
numerical aperture).
Statistics. Statistical analysis was performed using
OriginPro-8 (OriginLab, Northampton, MA, USA) or SPSS-9
(SPSS Inc., Chicago, IL, USA). Fear conditioning data
were analyzed using a repeated measures analysis of
variance (ANOVA) for tone-wise freezing scores (within
subject factor—tone presentation, between subject factor—
drug treatment). Student’s t-test was used to compare
freezing scores averaged across the first three tones. Arc
protein expression was analyzed separately in the LA, BA,
CeA, BNST and DG using a two-way ANOVA (between
subject factors—fear conditioning and drug treatment) or
Student’s t-test for independent samples, where applicable.
Significance was accepted for Po0.05.
Results
Acute systemic administration of fluoxetine enhances
conditioned fear memory. We first tested the effects of the
SSRI fluoxetine on Pavlovian auditory fear conditioning, an
amygdala-dependent form of fear learning in which an animal
rapidly learns to associate a previously innocuous tone with
an aversive footshock. Re-exposure to the tone alone elicits
a conditioned response, such as cessation of locomotor
activity or ‘freezing’, which we used as a behavioral measure
for the learned association. Rats were administered a single
injection of fluoxetine (10 mg kg 1, i.p.) or saline 1 h before
fear conditioning (Figure 1a). We found that fluoxetine did not
significantly change freezing during the conditioning session
when all tones were included in the analysis (Figure 1b;
repeated measures ANOVA: F(1,25)¼ 2.73, P¼ 0.11). How-
ever, we did find that fluoxetine-treated rats exhibited higher
freezing than saline-treated rats to the third tone
(t(12.96)¼ 2.46, Po0.05), consistent with previous studies
showing an enhancement in learning following acute SSRI
administration.16 Thus, there is a possibility that in our
experiment, the fluoxetine group learned fear faster but then
approached maximal levels of freezing faster. Interestingly,
presentation of the tone alone the next day during the testing
session elicited significantly higher freezing in fluoxetine-
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Figure 1 Acute systemic administration of fluoxetine enhances conditioned fear memory. (a) Schematic representation of the experimental protocol. Rats were habituated
to the conditioning and testing context and injected with saline or fluoxetine (10mg kg 1, i.p.) on the following day. One hour after injection, they were conditioned with five
conditioned stimulus–unconditioned stimulus (CS-US) pairings and tested for conditioned fear to three CS presentations on the following day. (b) Percentage of time spent
freezing in response to tone presentations on the conditioning day. (c) Percentage of time spent freezing in response to tone presentations on the testing day. (d) Percentage
of time spent freezing to all three tones on the testing day. Saline (sal): N¼ 13, fluoxetine (flx): N¼ 14. Error bars indicate mean±s.e.m. and *Po0.05.
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treated rats than saline-treated controls (Figure 1c; repeated
measures ANOVA: F(1,25)¼ 4.33, Po0.05 and Figure 1d;
t(25)¼ 2.1, Po0.05). The baseline levels of freezing mea-
sured during the 30-s period immediately before tone onset
did not differ between the groups (t(25)¼ 0.08, P¼ 0.94),
indicating that the enhancement in fear elicited by fluoxetine
was specific to the learned association. These results are
consistent with a previous study showing that a single
injection of the SSRI citalopram before fear conditioning also
enhances the acquisition of auditory fear memory.16
Acute systemic fluoxetine administration enhances Arc
protein expression in the CeA but not LA or BA. We next
investigated which specific components of the neural circuitry
underlying fear learning might serve as substrates for the
fear-enhancing effect of fluoxetine. An effective strategy for
such an analysis comes from numerous studies in which the
IEG Arc has been used to identify cells that are activated and
undergo plasticity in response to behaviorally relevant
stimuli.34–38 Using this approach, a recent study has shown
that auditory fear conditioning induces Arc expression in the
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Figure 2 Acute systemic fluoxetine treatment before fear conditioning leads to an increase in Arc (activity-regulated cytoskeleton-associated protein) expression in the
central nucleus (CeA), but not lateral (LA) or basal nucleus (BA) of the amygdala. (a) Schematic representation of the experimental protocol. Rats were habituated to the
conditioning context and injected with saline or fluoxetine (10mg kg 1 , i.p.) on the following day. Rats were either conditioned an hour after the injection and killed 2 h later
(saline- and fluoxetine-conditioned groups) or were directly killed 3 h after the injection (saline and fluoxetine naive groups). The brain tissue was then processed for
immunohistochemistry. (b) Low magnification images of brain sections from the four treatment groups to show Arc protein expression in the amygdala; bar¼ 500mm. (c–e)
representative images of Arc protein expression in the LA, BA and CeA, respectively; bar¼ 40mm. (f–h) Quantification of Arc-expressing cells across the four treatment
groups in the LA, BA and CeA, respectively. Saline naive (sal naive): N¼ 4, fluoxetine naive (flx naive): N¼ 4, saline conditioned (sal cond): N¼ 6, fluoxetine conditioned (flx
cond.): N¼ 6. Error bars indicate mean±s.e.m. and *Po0.05.
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LA and BA and that this upregulation of Arc is essential for
the expression of fear memory.27 We therefore hypothesized
that acute fluoxetine administration may enhance fear
memory by promoting plasticity in the LA and BA, thereby
leading to an increase in Arc protein expression in these
regions. To test this hypothesis, we administered a single
injection of fluoxetine (10 mg kg 1, i.p.) to rats 1 h before fear
conditioning. Two hours after conditioning, the rats were
killed and behaviorally induced Arc protein expression was
quantified in the LA, BA and CeA (Figure 2a). To dissociate
the effects of fluoxetine on baseline amygdala activity from
those specifically triggered by fear conditioning, we injected a
separate group of naive rats with the same dose of
fluoxetine, returned them to their home cage and killed them
3 h later (Figure 2a). Statistical analysis using a two-way
ANOVA showed a significant effect of fear conditioning in the
LA and BA (LA: F(1,16)¼ 11.81, Po0.01; BA: F(1,16)¼ 15.11,
Po0.01), indicating that there was more Arc protein
expression in both the regions of fear conditioned animals
than naive controls (Figures 2b–d, f and g). This is in
agreement with earlier work showing that Arc expression is
induced by auditory fear conditioning in these sub-regions of
the amygdala.27 Strikingly, Arc expression in the LA and BA
was not affected by pre-treatment with fluoxetine (LA:
F(1,16)¼ 0.10, P¼ 0.76; BA: F(1,16)¼ 0.002, P¼ 0.96;
Figures 2b–d, f and g), and there was no interaction between
fear conditioning and fluoxetine treatment (LA: F(1,16)¼ 0.95,
P¼ 0.34; BA: F(1,16)¼ 0.37, P¼ 0.55). By contrast, a two-way
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Figure 3 Acute systemic fluoxetine treatment induces Arc (activity-regulated cytoskeleton-associated protein) expression in the bed nucleus of the stria terminalis (BNST).
(a) Schematic representation of the experimental protocol. Rats were habituated to the conditioning context and injected with saline or fluoxetine (10 mg kg 1, i.p.) on the
following day. Rats were conditioned an hour after the injection and killed 2 h later. The brain tissue was then processed for immunohistochemistry. (b) Left, sample coronal
brain section containing the BNST, marked in a red dotted circle (Paxinos and Watson31); right, schematic of the principal BNST sub-regions (STLD, BNST lateral-dorsal or
oval nucleus; STLP, BNST lateral-posterior; STLV, BNST lateral-ventral; STMV, BNST medial-ventral; STMA, BNST medial-anterior; ac, anterior commissure, ic, internal
capsule). (c) Representative images of Arc protein expression in the BNST. Top panel: low magnification images of the BNST from the saline (left)- and fluoxetine (right)-
injected rats; bar¼ 500mm; bottom panel: higher magnification images of the BNST from the top panel; bar¼ 50mm. (d) Quantification of Arc-expressing cells in the BNST.
Saline conditioned (sal): N¼ 3, fluoxetine conditioned (flx): N¼ 3. Error bars indicate mean±s.e.m. and *Po0.05.
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ANOVA revealed a significant main effect of fluoxetine
treatment on Arc protein expression in the CeA
(F(1,16)¼ 9.26, Po0.01; Figures 2b, e and h). Pairwise
comparisons reveal that while systemic fluoxetine treatment
had no significant effect in naive animals, rats treated with
fluoxetine before fear conditioning showed significantly
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enhanced Arc protein expression in the CeA compared with
saline-treated rats (Tukey’s HSD (honestly significant differ-
ence), Po0.05; Figure 2h). Fear conditioning also had a
significant effect on Arc expression in the CeA (F(1,16)¼ 5.89,
Po0.05; Figure 2h). However, the interaction between fear
conditioning and fluoxetine treatment was not significant
(F(1,16)¼ 2.98, P¼ 0.10). These results suggest that the
facilitation of fear memory by acute systemic treatment with
fluoxetine is accompanied by activation of the CeA and raise
the possibility that this activation may underlie the behavioral
effect.
Acute systemic fluoxetine administration induces Arc
protein expression in the BNST. The CeA and the BNST
serve as the principal output structures of the extended
amygdaloid complex that project to the brainstem and
hypothalamus and mediate the expression of fear
responses.23,24,39 In addition to being highly interconnected,
the BNST and CeA have been shown to have important roles
in modulating fear and anxiety.40–42 Given this anatomical
and functional relationship and our above finding that acute
systemic fluoxetine enhanced Arc expression in the CeA, we
examined the pattern of Arc protein in the BNST 2 h after rats
pre-treated with acute systemic fluoxetine were fear condi-
tioned (Figure 3a). Consistent with our hypothesis, we found
that a single injection of fluoxetine also triggered Arc
expression in the dorsolateral region of the BNST (Figures
3c and d; t(2.1)¼ 4.28, Po0.5).
Finally, we examined whether Arc expression is enhanced
by fluoxetine in other brain regions involved in fear learning.
Previous work has shown that an acute SSRI injection
decreases contextual fear conditioning,43,44 a form of fear
learning that is hippocampal-dependent.45,46 Strikingly, in
contrast to the CeA and the BNST, we found that fluoxetine
treatment had the opposite effect on the DG of the
hippocampus, a brain region that has been previously
implicated in antidepressant action.47 Acute fluoxetine treat-
ment significantly decreased Arc protein expression in the DG
in both the naive and fear-conditioned animals
(Supplementary Figure S1; F(1,16)¼ 19.41, Po0.001), while
fear conditioning itself had no effect on Arc expression
(Supplementary Figure S1; F(1,16)¼ 0.07, P¼ 0.79).
Direct local infusion of fluoxetine into the CeA does not
enhance conditioned fear memory. Our results demon-
strate that a systemic injection of fluoxetine enhances Arc
protein expression in two output nuclei of the extended
amygdala: the BNST and the CeA. To determine whether
fluoxetine is acting directly on neurons in these two
structures to enhance fear conditioning, we tested the effects
of local infusions of fluoxetine targeted at either the CeA or
the BNST.
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context and infused with saline or fluoxetine (9mg per side) in the CeA or BNST on the following day. Fifteen minutes after the drug infusion, they were conditioned with two
conditioned stimulus–unconditioned stimulus (CS-US) pairings. Two hours after conditioning, they were killed, and the brain tissue was processed for immunohistochemistry. (b)
Representative images of Arc protein expression in the CeA. Top panel: low magnification images of the amygdala from the saline-infused (left) and fluoxetine-infused (right)
rats; bar¼ 500mm; bottom panel: high magnification images of the CeA from the top panel; bar¼ 50mm. (c) Quantification of Arc-expressing cells in the CeA. Saline infusion
(sal): N¼ 10, fluoxetine infusion (flx)  9mg per side: N¼ 9. Error bars indicate mean±s.e.m. and *Po0.05. BA, basal nucleus of the amygdala; LA, lateral nucleus of the
amygdala.
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We first tested the possibility that activation of CeA by
fluoxetine is sufficient to modify fear behavior. If this is true,
then local infusion of fluoxetine into the CeA before
conditioning should also enhance auditory fear memory, as
was observed with systemic treatment. We bilaterally infused
fluoxetine (9mg per side) directly into the CeA ( 2.5 mm AP,
þ / 4.3 mm ML,  8.0 mm DV) 15 min before the condition-
ing session and measured CS-elicited freezing behavior 24 h
later (Figure 4a). Intra-CeA fluoxetine infusions did not affect
freezing during the conditioning session (Figure 4b; repeated
measures ANOVA: F(1,14)¼ 0.59, P¼ 0.46). Surprisingly, we
found that intra-CeA fluoxetine infusions before conditioning
also did not affect freezing measured during the testing
session (Figure 4c; repeated measures ANOVA:
F(1,14)¼ 0.10, P¼ 0.76 and Figure 4d; t(14)¼ 0.2528,
P¼ 0.80). This suggests that targeted infusion of fluoxetine
into the CeA alone is not sufficient to produce the same
behavioral effects as acute systemic treatment.
Direct local infusion of fluoxetine into the bed nucleus of
the stria terminalis (BNST), is sufficient to enhance
conditioned fear memory. Given that Arc expression was
also enhanced in the BNST following systemic fluoxetine
administration coupled with fear conditioning, we next
examined whether local infusions of fluoxetine into the BNST
would enhance fear conditioning. We bilaterally infused rats
with fluoxetine (6 or 9 mg per side) in the BNST 15 min before
fear conditioning and measured the freezing response to the
CS 24 h later (Figure 4a). These infusions targeted the
dorsolateral and dorsomedial nuclei of the BNST ( 0.6 mm
AP, þ / 1.5 ML,  6.5 mm DV), and infusion cannulae
tracks in all the experimental animals were limited to 0.12 to
 0.72 mm Bregma (Figure 4h). These coordinates were
chosen based on earlier studies48 that characterized the
electrophysiological properties of BNST neurons in the area
dorsal to the anterior commissure, between 0.0 and
 0.6 mm Bregma. Intra-BNST fluoxetine infusions did not
affect freezing during the conditioning session (Figure 4e;
repeated measures ANOVA: F(1,15)¼ 0.01, P¼ 0.91). Inter-
estingly, we found that the intra-BNST fluoxetine enhanced
fear memory recall during the testing session 24 h later.
Moreover, this fear-enhancing effect was dose-dependent
(Figure 4g; one-way ANOVA: F(2,20)¼ 7.80, Po0.01).
Although the lower dose of 6 mg per side did not affect
memory recall (Figure 4g; Tukey’s HSD: P¼ 0.99), a higher
dose of 9 mg per side was sufficient to elicit a significant
enhancement in fear memory during the testing session
(Figure 4f; repeated measures ANOVA: F(1,15)¼ 8.52,
Po0.05 and Figure 4g; Tukey’s HSD: Po0.01). Thus, a
single infusion of fluoxetine directly into the BNST produced
the same behavioral effect on fear memory recall as a single
systemic injection of fluoxetine.
Direct local infusion of fluoxetine into the BNST before
fear conditioning enhances Arc protein expression in
the CeA. Together, our results suggest that the BNST may
be a primary site of action for fluoxetine and may mediate the
behavioral enhancement of fear memory seen after acute
systemic fluoxetine treatment. However, as shown earlier,
systemic fluoxetine treatment also led to enhanced Arc
expression in the CeA. Does direct infusion of fluoxetine into
the BNST cause the same effect in the CeA? To address this
question, behaviorally induced Arc protein expression was
evaluated in the CeA of rats infused with fluoxetine (9mg per
side) in the BNST 15 min before fear conditioning and killed
2 h later (Figure 5a). We found that intra-BNST fluoxetine
infusion did enhance Arc protein expression in the CeA
(Figures 5b and c; t(10.7)¼ 2.6, Po0.5). Thus, similar to
systemic acute administration of fluoxetine, the facilitation of
fear memory recall caused by intra-BNST fluoxetine infu-
sions is also accompanied by the induction of Arc protein
expression in the CeA.
Discussion
Consistent with earlier reports,16 we found that a single injection
of fluoxetine immediately before conditioning enhances the
recall of fear memory a day later. Surprisingly, fluoxetine pre-
treatment was accompanied by increased Arc protein expres-
sion in the CeA and BNST but not in the LA or BA. This is
consistent with recent reports identifying a critical role for the
CeA in the acquisition of auditory fear memory.19,49 Although
enhanced Arc expression in the CeA suggested a potential role
for this structure in enhancing fear memory after acute systemic
treatment with SSRIs, we found that local infusion of fluoxetine
directly into the CeA did not affect fear memory. Instead, local
infusion of fluoxetine into the BNST, a closely related
component of the extended amygdala, was sufficient to
enhance both fear memory and Arc protein expression in the
CeA. Together these results suggest that systemically adminis-
tered fluoxetine may act within the BNST to drive both Arc
expression in the CeA and enhance fear learning.
The acute effects of SSRI treatment on fear and anxiety.
The acute effects of SSRIs have been demonstrated in
numerous models of anxiety-like behavior.11–15 The amyg-
dala is known to be an important component of anxiety
circuits in the brain50,51 and aberrant amygdala activity is
associated with affective symptoms of numerous psychiatric
disorders.52–55 Furthermore, there are reports that acute
administration of SSRIs increase amygdala activity56,57 and
fear-potentiated startle responses in healthy humans.58
Although this work implicates the amygdala in the acute
anxiogenic effects of SSRIs, the key unresolved issue was to
identify specific components of the amygdala that mediate
these effects.
Identifying amygdalar circuits involved in the acute
effects of SSRIs. To probe the neural substrates underlying
the acute effects of fluoxetine, we analyzed the impact of
fluoxetine on the expression of Arc, an IEG that is induced by
behaviorally relevant stimuli and has a critical role in
consequent synaptic plasticity.59,60 Arc mRNA undergoes
rapid transport to dendrites and is enriched at local sites of
synaptic activity, a process requiring NMDA (N-methyl-D-
aspartate)-receptor activation.61 Fear conditioning, which
also requires activation of NMDA receptors,62,63 is known
to induce the expression of Arc protein in both the LA and
BA. Furthermore, this upregulation of Arc is required for the
subsequent expression of fear memory.27 Although previous
studies report that acute SSRI treatment modulates IEG
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expression in naive as well as in stressed animals in several
brain areas, including the basolateral amygdala (BLA),
medial amygdala, CeA and BNST,15,64–66 nothing is known
about how SSRIs affect the induction of Arc expression in
sub-regions of the amygdala following cued fear conditioning.
We hypothesized that acute SSRI treatment may potentiate
fear memory by affecting activity of the LA and BA.
Surprisingly, we found that fluoxetine pre-treatment had no
effect on Arc expression in the LA or BA, despite fear
conditioning itself enhancing Arc expression in these areas in
the absence of fluoxetine. However, Arc expression in the
CeA was significantly enhanced with fluoxetine treatment,
suggesting a role for CeA activation in fluoxetine-induced
potentiation of fear memory.
It is interesting to note that in our study the effect of acute
fluoxetine is evident only in the CeA of fear conditioned, but
not naive, animals. It is possible that fluoxetine, which
increases extracellular levels of serotonin by blocking the
serotonin transporter, does not change Arc levels under
baseline conditions, because levels of serotonin are low.
During fear conditioning, serotonin levels increase67–69 and
are further elevated by blockade of the serotonin transporter,
both of which appear to be required for Arc expression in the
CeA to increase.
Role of the extended amygdala. The CeA is the primary
output nucleus of the amygdaloid complex that mediates the
expression of conditioned fear responses via its projections
to downstream brain areas.23 Although much attention has
focused on the role of the BLA in the acquisition of auditory
fear conditioning, several recent studies show that the CeA
may function in parallel with the BLA to make distinct
contributions to fear and anxiety-like behavior. Indeed,
inactivation of the CeA impairs fear learning,70,71 and rats
with BLA lesions can learn conditioned fear responses in an
associative, CeA-dependent manner.72,73 Importantly, activ-
ity-dependent plasticity within the CeA is essential for the
acquisition of fear conditioning.25,65,66 Moreover, diverse
agents ranging from alcohol to neuropeptides like oxytocin
are known to produce anxiolytic effects by modulating
inhibitory microcircuits in the CeA.74,75
Although our data suggest that elevation of Arc expression
in CeA may be a neural correlate of the facilitation of fear
memory by systemic fluoxetine, direct infusion of fluoxetine
into the CeA failed to enhance fear memory. This indicates
that fluoxetine does not mediate its behavioral effects on fear
conditioning by acting directly on the CeA and instead raises
the possibility that fluoxetine may act on other brain areas that,
in turn, project to the CeA to modulate fear memory. Indeed,
systemic fluoxetine treatment similarly increased Arc protein
expression in the BNST. We found that direct infusion of
fluoxetine into the BNST before conditioning was sufficient to
enhance both fear memory, as well as Arc expression in the
CeA. In other words, the direct action of fluoxetine on the
BNST has the same functional consequences as systemic
treatment.
To evaluate whether the upregulation of Arc expression is
specific to the CeA and BNST, we also analyzed Arc
expression in the DG of the hippocampus. We found that
fluoxetine treatment decreased Arc expression in the DG
regardless of whether or not animals were fear conditioned,
providing further support for a specific role of the extended
amygdala in the acute effects of fluoxetine. This result is
consistent with earlier reports of a decrease in hippocampus-
dependent contextual fear memory following acute SSRI
treatment.43,44 These results are also interesting in light of
studies that implicate the hippocampus in antidepressant
effects47 and reports of contrasting effects of stress on the
hippocampus and amygdala76 and warrant further investiga-
tion in future studies.
The involvement of both the BNST and CeA is intriguing
because of substantial evidence that the two regions mediate
distinct fear responses, despite their extensive similarities.
The CeA is an integral part of fear circuits that mediate
stimulus-specific conditioned fear responses to discrete
sensory cues and is essential for the acquisition and
expression of auditory fear conditioning.17,26 On the other
hand, the BNST is not necessary for acquisition or expression
of fear to a discrete conditioned cue.23,77–79 Instead, the
BNST mediates non-specific, ‘anxiety–like’ sustained fear
states in response to more diffuse environmental contingen-
cies, such as light-induced startle and corticotropin-releasing
factor-induced anxiety.26 However, many recent studies
suggest that the two fear systems do interact and are not
completely independent. For instance, although the BNST is
not required for conditioned fear responses to brief sensory
cues, it is required for conditioned responses to long duration
cues paired with a shock.80,81 The BNST is also required for
contextual fear conditioning.77,82,83 Further, animals with
BNST lesions display less fear generalization.82 Together,
these studies suggest that although the BNST is not involved
directly in the formation of brief stimulus-specific memory,
other aspects of conditioned fear, such as the effect of context
and stimulus specificity, may be modulated by the BNST.
Our results suggest that although the BNST is not normally
required for the acquisition and expression of conditioned fear
memory, acute systemic fluoxetine treatment recruits the
BNST into the fear circuitry, leading to an increase in fear
memory, possibly mediated via the CeA. Although our
experiments suggest that pre-treatment with fluoxetine
engages the BNST during fear learning, our data does not
address whether the BNST is also active during memory
recall. Future studies aimed at measuring IEG expression in
the BNST during fear expression may help in addressing this
possibility. Further, studies involving transient inactivation of
the BNST during the conditioning or testing sessions in
different groups of rats pre-treated with fluoxetine will help
verify a role for the BNST in the acquisition and expression of
conditioned fear.
The results presented here raise questions regarding how
SSRIs modulate BNST function. The increased availability of
serotonin (5-hydroxytryptamine (5-HT)) due to SSRIs may act
on numerous candidate 5-HT receptors in the BNST.41,84
Interestingly, activation of the 5-HT2A/2C/7 receptor sub-types
in vitro mediates an excitatory response to 5-HT that may be
anxiogenic.41 Consistent with this, pre-treatment of rats with a
5-HT2C antagonist blocked the acute fear-enhancing effect of
the SSRI citalopram.28 Conversely, systemic activation of 5-
HT2C receptors in rats is anxiogenic
85 and increases the
expression of c-fos in the anterolateral BNST.86 The activation
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of BNST by acute SSRI treatment may therefore be mediated
by the activation of specific 5-HT receptors on BNST neurons,
a possibility that awaits further analysis.
In conclusion, our findings demonstrate that the direct
action of fluoxetine in BNST successfully replicates the
consequences of acute systemic fluoxetine treatment in terms
of a molecular marker of activity and plasticity (induction of Arc
expression), its enhanced expression in a specific circuit
within the amygdala (CeA) and its behavioral impact
(enhanced fear memory recall). The BNST appears to have
a novel modulatory role in generating stimulus-specific
conditioned fear responses, which are also known to involve
the CeA.87 In this regard, our results reflect the importance of
expanding our focus from the BLA to output structures of the
amygdaloid complex, such as the CeA and BNST. Future
studies will be needed to address what the precise role of the
CeA is in the acute effects of SSRIs on fear memory and
whether this is any different from its normal role during fear
acquisition and expression in the absence of SSRIs. This will
require an understanding of what specific cellular populations
and connections between the CeA and BNST mediate such
modulatory influences. Such an approach is likely to provide a
more comprehensive experimental framework for studying
these short-term undesirable effects as well as the therapeutic
effects of long-term SSRI treatment.
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